摘要
目的观察羟基喜树碱、吡柔比星与丝裂霉素膀胱内灌注预防浅表性膀胱肿瘤复发的疗效。方法将182例膀胱肿瘤术后患者分成羟基喜树碱组、吡柔比星组及丝裂霉素组,进行膀胱内灌注并随访观察三年。结果羟基喜树碱、吡柔比星及丝裂霉素三组患者无瘤生存率1年为69.4%（43/62）,86.2%（50/58）,64.5%（40/62）;2年为69.4%（25/36）,77.6%（45/58）,50%（31/62）;3年为64.5%（40/62）,69%（40/58）,50%（31/62）。结论三种药物膀胱内灌注预防浅表性膀胱肿瘤复发3年无瘤生存率无显著性差异。
Objective To investigate the effect of intravesical therapy with HCTP THP and Mitomycin C on preventing postoperative recurrence of superficial bladder cancer.Methods The series included 182 patients with superficial bladder cancer assigned to hydroxycamptothecin、hydrochloride pirarubicin and mitomycin C groups and finished a 3-year follow-up.Results The one-year disease free survival rate of hydroxycamptothecin、 hydrochloride pirarubicin and mitomycin C was 69.4%（43/62）,86.2%（50/58）,64.5%（40/62）;the two-year disease free survival rate was 69.4%（25/ 36）,77.6%（45/58）,50%（31/62）;the three-year rate was 64.5%（40/62）,69%（40/58）,50%（31/62）.Conclusion There is no significant difference in the effects of intravesical therapy with hydroxycamptothecin、hydrochloride pirarubicin and mitomycin C on preventing postoperative recurrence of superficial bladder cancer concerning the disease free survival rates.
作者
鲁栋梁
鲜述彦
李建勇
LU Dong-liang,XIAN Shu-yan,LI Jian-yong （Department of Neurology,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,China）
出处
《医学信息》
2010年第20期3767-3768,共2页
Journal of Medical Information
关键词
浅表型膀胱肿瘤
膀胱灌注
superficial bladder cancer
irrigation bladder
